X

Trial Profile

A phase 2 study of one of the SPY002 molecules in ulcerative colitis exploring quarterly monotherapies and combinations

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 17 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SPY 002 (Primary)
Indications Ulcerative colitis
Focus Adverse reactions; Therapeutic Use

Most Recent Events

13 Jan 2025 According to Spyre Therapeutics media release, the initial open label monotherapy data from this study are expected beginning in mid-2026, with full placebo-controlled data expected in 2027.
11 Dec 2024 New trial record
02 Dec 2024 According to Spyre Therapeutics media release, the company plans to initiate this study in 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com